{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:52:49Z","timestamp":1795024369872,"version":"4.10.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["100CM-KMU-09"],"award-info":[{"award-number":["100CM-KMU-09"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-TC109B05"],"award-info":[{"award-number":["KMU-TC109B05"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["MOST 108\u20132314-B-037 -066 -MY3"],"award-info":[{"award-number":["MOST 108\u20132314-B-037 -066 -MY3"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-KI110002"],"award-info":[{"award-number":["KMU-KI110002"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH109-9R06"],"award-info":[{"award-number":["KMUH109-9R06"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH-DK(C)110011"],"award-info":[{"award-number":["KMUH-DK(C)110011"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH-DK(C)110004"],"award-info":[{"award-number":["KMUH-DK(C)110004"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH109-9R05"],"award-info":[{"award-number":["KMUH109-9R05"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12072-023-10506-z","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T19:03:14Z","timestamp":1679943794000},"page":"550-561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness and safety of 8-week glecaprevir\/pibrentasvir in HCV treatment-na\u00efve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry"],"prefix":"10.1007","volume":"17","author":[{"given":"Te-Sheng","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Tao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chu","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Won","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Nan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jong","family":"Bair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Lang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chieh","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yuan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzong-Hsi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Ting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lein-Ray","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guei-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Neng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hsuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chih","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-9519","authenticated-orcid":false,"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"10506_CR1","unstructured":"World Health Organization. Hepatitis C. Geneva, Switzerland: WHO. 2022 https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed Sep 2022"},{"key":"10506_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.35772\/ghm.2021.01064","volume":"3","author":"RN Chien","year":"2021","unstructured":"Chien RN, Lu SN, Pwu RF, Wu GH, Yang WW, Liu CL. Taiwan accelerates its efforts to eliminate hepatitis C. Glob Health Med 2021;3:293\u2013300","journal-title":"Glob Health Med"},{"key":"10506_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","volume":"14","author":"AP Thrift","year":"2017","unstructured":"Thrift AP, El-Serg HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol 2017;14:122\u2013132","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10506_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Inf Dis 2012;206:469\u2013477","journal-title":"J Inf Dis"},{"key":"10506_CR5","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/gutjnl-2018-316234","volume":"67","author":"P Cacoub","year":"2018","unstructured":"Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut 2018;67:2025\u20132034","journal-title":"Gut"},{"key":"10506_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/bmb\/ldv004","volume":"113","author":"MD Sadler","year":"2015","unstructured":"Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull 2015;113:31\u201344","journal-title":"Br Med Bull"},{"key":"10506_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017;166:637\u2013648","journal-title":"Ann Intern Med"},{"key":"10506_CR8","unstructured":"World Health Organization. Global hepatitis report. Geneva, Switzerland: WHO. 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789?sequence=1. Accessed in Sep 2022"},{"key":"10506_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.12.007","volume":"18","author":"MJ Zoratti","year":"2020","unstructured":"Zoratti MJ, Siddiqua A, Morassut RE, Zeraatkar D, Chou R, van Holton J, et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis. EClinicalMedicine 2020;18: 100237","journal-title":"EClinicalMedicine"},{"key":"10506_CR10","doi-asserted-by":"publisher","first-page":"13543","DOI":"10.1038\/s41598-021-93095-x","volume":"11","author":"KC Chang","year":"2021","unstructured":"Chang KC, Tung SY, Wei KL, Shen CH, Hsieh YY, Chen WM, et al. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. Sci Rep 2021;11:13543","journal-title":"Sci Rep"},{"key":"10506_CR11","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","unstructured":"AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477\u20131492","journal-title":"Clin Infect Dis"},{"key":"10506_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","volume":"119","author":"ML Yu","year":"2020","unstructured":"Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YS, et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formos Med Assoc 2020;119:1019\u20131040","journal-title":"J Formos Med Assoc"},{"key":"10506_CR13","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol 2020;73:1170\u20131218","journal-title":"J Hepatol"},{"key":"10506_CR14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S2468-1253(17)30053-5","volume":"2","author":"B Emmanuel","year":"2017","unstructured":"Emmanuel B, Wilson EM, O\u2019Brien TR, Kottilil S, Lau G. Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol 2017;2:832\u2013836","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10506_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40121-021-00410-0","volume":"10","author":"M Andreoni","year":"2021","unstructured":"Andreoni M, Perri GD, Persico M, Marcellusi A, Ethgen O, Sanchez Y, et al. Addressing HCV elimination barriers in Italy: healthcare resource utilization and cost impact using 8 weeks\u2019 glecaprevir\/pibrentasvir therapy. Infect Dis Ther 2021;10:763\u2013774","journal-title":"Infect Dis Ther"},{"key":"10506_CR16","doi-asserted-by":"publisher","first-page":"23473","DOI":"10.1038\/s41598-021-03006-3","volume":"11","author":"CF Huang","year":"2021","unstructured":"Huang CF, Kuo HT, Chang TS, Lo CC, Hung CH, Huang CW, et al. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Sci Rep 2021;11:23473","journal-title":"Sci Rep"},{"key":"10506_CR17","unstructured":"AbbVie. Mavyret (glecaprevir\/pibrentasvir) US prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209394s008lbl.pdf. Accessed Sep 2022"},{"key":"10506_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown","year":"2020","unstructured":"Brown RS, Buti M, Rodrigues L, Chulanov V, Chung WL, Aguilar H, et al. Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol 2020;72:441\u2013449","journal-title":"J Hepatol"},{"key":"10506_CR19","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","volume":"37","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, et al. Real-world clinical practice use of 8-week glecaprevir\/pibrentasvir in treatment-na\u00efve patients with compensated cirrhosis. Adv Ther 2020;37:4033\u20134042","journal-title":"Adv Ther"},{"key":"10506_CR20","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s12325-020-01301-5","volume":"37","author":"SL Flamm","year":"2020","unstructured":"Flamm SL, Kort J, Marx SE, Strezewski J, Dylla DE, Bacon B, et al. Effectiveness of 8-week Glecaprevir\/Pibrentasvir for treatment-na\u00efve, compensated cirrhotic patients with chronic hepatitis C infection. Adv Ther 2020;37:2267\u20132274","journal-title":"Adv Ther"},{"key":"10506_CR21","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.3390\/jcm10225236","volume":"10","author":"PY Su","year":"2021","unstructured":"Su PY, Chen YY, Lai JH, Chen HM, Yao CT, Liu IL, et al. Real-world experience of chronic hepatitis c-related compensated liver cirrhosis treated with glecaprevir\/pibrentasvir: a multicenter retrospective study. J Clin Med 2021;10:5236","journal-title":"J Clin Med"},{"key":"10506_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/liv.14829","volume":"41","author":"H Wedemeyer","year":"2021","unstructured":"Wedemeyer H, Erren P, Naumann U, Rieke A, Stoehr A, Zimmerman T, et al. Glecaprevir\/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: real-world data from the German Hepatitis C-Registry. Liver Int 2021;41:949\u2013955","journal-title":"Liver Int"},{"key":"10506_CR23","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1111\/liv.14937","volume":"41","author":"H Klinker","year":"2021","unstructured":"Klinker H, Naumann U, R\u00f6ssle M, Berg T, Bondin M, Lohmann K, et al. Glecaprevir\/pibrentasvir for 8 weeks in patients with compensated cirrhosis: safety and effectiveness data from the German Hepatitis C-Registry. Liver Int 2021;41:1518\u20131522","journal-title":"Liver Int"},{"issue":"8","key":"10506_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272567","volume":"17","author":"YH Lu","year":"2022","unstructured":"Lu YH, Lu CK, Chen CH, Tung SY, Chen YH, Yen CW, et al. Comparison of 8- versus 12-weeks of glecaprevir\/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. PLoS ONE 2022;17(8): e0272567","journal-title":"PLoS ONE"},{"key":"10506_CR25","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1007\/s12325-022-02158-6","volume":"39","author":"M Cornberg","year":"2022","unstructured":"Cornberg M, Ahumada A, Aghemo A, Andreoni M, Bhagat A, Butrymowicz I, et al. Safety and effectiveness using 8 weeks of glecaprevir\/pibrentasvir in HCV-infected treatment-na\u00efve patients with compensated cirrhosis: the CREST study. Adv Ther 2022;39:3146\u20133158. https:\/\/doi.org\/10.1007\/s12325-022-02158-6","journal-title":"Adv Ther"},{"key":"10506_CR26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/liv.14849","volume":"41","author":"CY Chen","year":"2021","unstructured":"Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int 2021;41:1265\u20131277","journal-title":"Liver Int"},{"key":"10506_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40121-021-00576-7","volume":"11","author":"PN Cheng","year":"2022","unstructured":"Cheng PN, Mo LR, Chen CT, Chen CY, Huang CF, Kuo HT, et al. Sofosbuvir\/velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan. Infect Dis Ther 2022;11:485\u2013500. https:\/\/doi.org\/10.1007\/s40121-021-00576-7","journal-title":"Infect Dis Ther"},{"key":"10506_CR28","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/jvh.13586","volume":"28","author":"D H\u00fcppe","year":"2021","unstructured":"H\u00fcppe D, Stoehr A, Stoehr P, Stoehr S, Klinker H, Klinker G, et al. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: real-world data from the German Hepatitis C Registry (DHC-R). J Viral Hepat 2021;28:1474\u20131483","journal-title":"J Viral Hepat"},{"key":"10506_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12072-015-9680-7","volume":"10","author":"T Petersen","year":"2016","unstructured":"Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int 2016;10:310\u2013319","journal-title":"Hepatol Int"},{"key":"10506_CR30","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.jfma.2020.08.010","volume":"11","author":"WM Chen","year":"2020","unstructured":"Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, et al. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir\/pibrentasvir therapy. J Formos Med Assoc 2020;11:1593\u20131600","journal-title":"J Formos Med Assoc"},{"key":"10506_CR31","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","volume":"72","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Crrion JA, Curry M, Turnes J, Cornberg M, Negro F, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic hepatitis C infection: a meta-analysis. J Hepatol 2020;72:1112\u20131121","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10506-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10506-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10506-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:42:03Z","timestamp":1744213323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10506-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10506"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10506-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ming-Lung Yu: Research support from Abbvie, Abbott, BMS, Gilead, Merck and Roche. Consultant for Abbvie, Abbott, Ascletis, BMS, Gilead, J&J, Merck, Novartis, Pharmaessential and Roche. Speaker for Abbvie, Abbott, Ascletis, BMS, Gilead, Merck, Pharmaessential and Roche. Sheng-Shun Yang: Speaker for AbbVie, Bristol-Myers, Squibb, Gilead Sciences, Ipsen, and Merck Sharp & Dohme. Advisory board member for AbbVie, Gilead Sciences, Hoffmann-LaRoche, and Ipsen.\u00a0Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, Ching-Chu Lo, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Chia-Chi Wang, Jui-Ting Hu, Lein-Ray Mo, Chun-Ting Chen, Yi-Hsiang Huang, Chun-Chao Chang, Chia-Sheng Huang, Guei-Ying Chen, Chien-Neng Kao, Chi-Ming Tai, Chun-Jen Liu, Mei-Hsuan Lee, Pei-Chien Tsai, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wang-Long Chuang, Chi-Yi Chen, Kuo-Chih Tseng, and\u00a0Chao-Hung Hung\u00a0declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}